A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients.
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2013
At a glance
- Drugs Granulocyte-macrophage colony-stimulating factors; Isotretinoin; Monoclonal antibody 3F8
- Indications Neuroblastoma
- Focus Therapeutic Use
- 10 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Jan 2010 New source identified and integrated (M.D. Anderson Cancer Center).
- 10 Sep 2009 New trial record